Status:
COMPLETED
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid ...
Eligibility Criteria
Inclusion
- Active rheumatoid arthritis
- Inadequate response to stably dosed methotrexate
Exclusion
- Current therapy with any DMARD or biologic other than methotrexate
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
509 Patients enrolled
Trial Details
Trial ID
NCT00413660
Start Date
January 1 2007
End Date
August 1 2008
Last Update
January 18 2013
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Gilbert, Arizona, United States, 85234
2
Pfizer Investigational Site
Hot Springs, Arkansas, United States, 71913
3
Pfizer Investigational Site
Upland, California, United States, 91786
4
Pfizer Investigational Site
Denver, Colorado, United States, 80204